Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda, Eisai Shares Hit Hard by Clogs in New-Drug Pipeline (Japan)

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical and Eisai have both suffered severe stock plunges in the past few weeks despite positive earning reports. The drastic drops are largely the result of reported problems with two respective clinical trials. When Takeda announced on Oct. 29 that it would have to conduct more trials on its experimental hyperlipidemia treatment, its stock plummeted 900 billion yen. It has still not recovered, despite reported earnings that were up 12 percent. Eisai had the same problem when it reported promising profit margins for the first part of the year and still watched its stock drop 200 yen. Analysts say that tumble was caused by the delay of approval for its experimental Parkinson's disease treatment. Insiders explain that the seemingly inconsistent earnings and stock prices are due to investor fears about future patent expirations. Much of Takeda's and Eisai's success is built on the revenues of drugs whose patents will expire in 2010. If the companies do not obtain approval for their replacements in time, future earnings could go through the floor. (Click here for more

You may also be interested in...



China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel